Clinical Trial

Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Breast Cancer

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a prospective, open-label, single-center, randomized controlled Phase II clinical study aimed at evaluating the efficacy and safety of neoadjuvant imlunestrant combined with abemaciclib guided by the Ki67 index after 2 weeks in patients with ER+/HER2- breast cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-02-08.
Trial Details
NCT Number NCT07410559
Lead Sponsor Fudan University
Conditions Breast Cancer
Enrollment 189 participants
Start Date 2026-07-01
Primary Completion 2029-04-01 (estimated)
Study Completion 2031-07-01 (estimated)
Updated on ClinicalTrials.gov 2026-02-18